Shoring up the industry's valuations

Article Abstract:

In delivering on their promises to introduce a dynamic variety of drugs, technologies, and advanced platforms into the market, biotechnology firms have done an excellent job. However, biotech firms in the US should continue to work towards offering integrated pharma solutions and improve their skill in meeting the demands of the institutional investment community. Biotech firms will have to increase their capitalization and offer improved valuations.

Comment:

Biotech firms must work to increase valuations and stockholder value

Strategy & planning, Article

---

Recent patents in molecular evolution

Article Abstract:

List of eight patents approved in 2000-2001, with the names of the companies from throughout the world that sought the patents, patent numbers, a brief description of the patent, etc.

Syngenta AG, Phylos Inc., BioCatalytics, Enchira Biotechnology Corp., Yeda Research and Development, Omniscience Pharmaceuticals, Zeneca Group PLC, Kairos Scientific

---

Moving the gene patent debate forward

Article Abstract:

Overview of the ethical ramifications for granting biotechnology patents in the U.S. and Europe, toward finding common ground.

Europe

Similar abstracts:

• Abstracts: Clever branding campaign uses celebrities in postcards. Major circulation campaign targets Chinese-Americans. Brighter, better campaign
• Abstracts: The relative signalling power of dutch-auction and fixed-price self-tender offers and open-market share repurchases
• Abstracts: Southwest Strategies. Bender/Helper Impact
• Abstracts: Taylor-made interest rate relief. The true interest rate question. Wages threaten interest rates
• Abstracts: Biotech bloodshed. Rhein Biotech. GeneMedix plans generic biotech

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.